Product Description
Mechanisms of Action: AT2 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Spinifex Pty
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Chemotherapy-induced Peripheral Neuropathy|Neuralgia, Postherpetic|Neuropathic Pain|Pain Unspecified|Neuralgia|Peripheral Nervous System Diseases
Phase 1: Neuralgia, Postherpetic|Neuropathic Pain
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| JapicCTI-173816 | P2 |
Terminated |
Neuralgia |
2020-08-28 |
|
| EMPHENE | P2 |
Completed |
Neuralgia |
2019-07-16 |
|
| EMPADINE | P2 |
Completed |
Pain Unspecified |
2019-03-25 |
|
| EMPADINE | P2 |
Terminated |
Peripheral Nervous System Diseases |
2019-03-25 |